Market Recap: Exact Sciences Corp (EXAS)’s Negative Momentum, Closing at 47.82

For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.

The closing price of Exact Sciences Corp (NASDAQ: EXAS) was $47.82 for the day, down -1.40% from the previous closing price of $48.50. In other words, the price has decreased by -$1.40 from its previous closing price. On the day, 2.34 million shares were traded.

Ratios:

Our analysis of EXAS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.56 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 119.15. For the most recent quarter (mrq), Quick Ratio is recorded 1.92 and its Current Ratio is at 2.15. In the meantime, Its Debt-to-Equity ratio is 1.16 whereas as Long-Term Debt/Eq ratio is at 1.04.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on January 23, 2025, initiated with a Overweight rating and assigned the stock a target price of $70.

On August 28, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $75.

On June 27, 2024, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $70.Scotiabank initiated its Sector Outperform rating on June 27, 2024, with a $70 target price.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 13 ’24 when Conroy Kevin T bought 19,500 shares for $51.35 per share. The transaction valued at 1,001,325 led to the insider holds 1,074,191 shares of the business.

Baranick Brian sold 929 shares of EXAS for $65,030 on Oct 08 ’24. The EVP, GM, Precision Oncology now owns 12,758 shares after completing the transaction at $70.00 per share. On Oct 08 ’24, another insider, Baranick Brian, who serves as the Officer of the company, bought 929 shares for $70.00 each.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 3.22 while its Price-to-Book (P/B) ratio in mrq is 3.69.

Stock Price History:

Over the past 52 weeks, EXAS has reached a high of $79.62, while it has fallen to a 52-week low of $40.62. The 50-Day Moving Average of the stock is -12.50%, while the 200-Day Moving Average is calculated to be -14.69%.

Shares Statistics:

A total of 185.62M shares are outstanding, with a floating share count of 183.05M. Insiders hold about 1.46% of the company’s shares, while institutions hold 99.50% stake in the company.

Most Popular